Corneal Cross Linking
Corneal Collagen Cross Linking (CXL) is a newly approved treatment for Keratoconus that works by increasing collagen crosslinks and strengthening the cornea to help halt the progression of Keratoconus.
Corneal Cross Linking Overview
About Corneal Cross Linking
In April 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate sodium in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate sodium ophthalmic solution) and the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.
Corneal Cross Linking stiffens corneas that have been weakened by disease. They are the first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus, and we offer them to patients in our practice.
The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.